View Post

Breast Cancer Drug Promising in Phase 3 Trial

In Clinical Trials by Barbara Jacoby

By: Steven Reinberg From: consumer.healthday.com For women with advanced breast cancer who carry the BRCA1 and BRCA2 gene mutations, an experimental drug could improve survival, a new study suggests. The BRCA mutations are linked with a greater risk for aggressive breast and ovarian cancer. The drug, talazoparib, works by blocking an enzyme called poly ADP ribose polymerase (PARP), thus preventing …

View Post

Pfizer Gains Priority Review For Breast Cancer Drug, Can It Succeed?

In In The News by Barbara Jacoby

By: Terry Chrisomalis From: seekingalpha.com Summary Pfizer obtains priority review for talazoparib in treating patients with germline BRCA-mutated breast cancer, with FDA decision date by December 2018. Treatment with talazoparib in BRCA-mutated breast cancer reduced the risk of disease progression by 46%. If talazoparib is approved by the FDA it will have to go up against other competing drugs for the same …